A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis*1
| Autor: | Raphael Rubin, Robert L. Carithers, Edwin H. Eigenbrodt, Mitchell L. Shiffman, Rodney S. Markin, Stephen S. Rossi, James L. Boyer, Rowen K. Zetterman, Danyu Lin, Alan F. Hofmann, Marion G. Peters, Willis C. Maddrey, Guadalupe Garcia-Tsao, Velimir A. Luketic, Alexander B. West, Donald E. Wheeler, A. Scott Mills, Santiago J. Munoz, White Hm, Mary F. McDonald, Gregory F. Bonner, Burton Combes |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
medicine.medical_specialty
Hepatology Bile acid medicine.drug_class business.industry Bilirubin Biliary cirrhosis Placebo-controlled study Placebo medicine.disease Gastroenterology Ursodeoxycholic acid law.invention chemistry.chemical_compound Primary biliary cirrhosis chemistry Randomized controlled trial law Internal medicine medicine business medicine.drug |
| Zdroj: | Hepatology. 22:759-766 |
| ISSN: | 0270-9139 |
| Popis: | One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin ( or +2 (strata 3 and 4). Histology was favorably affected by ursodiol in patients in strata 1 and 2 but not in strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text